Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

doi:10.1159/000507889

Related publications

Article2020

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Chikara Ogawa, Joji Tani, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Hidenori Toyoda, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kojiro Michitaka, Yoichi Hiasa, Masatoshi Kudo

Article2016

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial

Masatoshi Kudo, Etsuro Hatano, Shinichi Ohkawa, Hirofumi Fujii, Akihide Masumoto, Junji Furuse, Yoshiyuki Wada, Hiroshi Ishii, Shuntaro Obi, Shuichi Kaneko, Seiji Kawazoe, Osamu Yokosuka, Masafumi Ikeda, Katsuaki Ukai, Sojiro Morita, Akihito Tsuji, Toshihiro Kudo, Mitsuo Shimada, Yukio Osaki, Ryosuke Tateishi, Gen Sugiyama, Paolo Abada, Ling Yang,

Article2024

Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

Silvia Camera, Margherita Rimini, Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Francesca Salani, Mariarosaria Marseglia, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach,

Article2016

Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma

Masatoshi Kudo, Sheng‐Long Ye, Keiko Nakajima, Riccardo Lencioni

Article2020

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

Masatoshi Kudo, Takuji Okusaka, Kenta Motomura, Izumi Ohno, Manabu Morimoto, Satoru Seo, Yoshiyuki Wada, Shinpei Sato, Tatsuya Yamashita, Masayuki Furukawa, Takeshi Aramaki, Seijin Nadano, Kazuyoshi Ohkawa, Hirofumi Fujii, Toshihiro Kudo, Junji Furuse, Hiroki Takai, Gosuke Homma, Reigetsu Yoshikawa, Andrew X. Zhu